Tricuspid Regurgitation Contribute to Growth of Tricuspid Valve Repair Market

Increasing healthcare expenditure has a direct influence on the rising number of surgical procedures. This, in turn, has contributed to the growth of the global tricuspid valve repair market. As per data provided by the WHO, the percentage increase in healthcare expenditure is more than percentage increase in GDP annually, particularly in low and middle-income group of countries. The growth in healthcare expenditure is supported by rising per capita income across the globe. In the U.S., as per estimation, approximately 2.5 million patient is diagnosed with mild to several tricuspid regurgitations. Further, around 200,000 new incidence of tricuspid is added annually.

In 90% of surgeries for tricuspid valve repair are executed in case aortic stenosis and mitral valve diseases, and the reaming surgeries are done only for tricuspid valve repair. Diagnosis of tricuspid stenosis and tricuspid regurgitation at early stage enable medical professional to treat the patients with heart valve defects, particularly tricuspid valve repair can be done using surgery.

Increasing incidence of mitral valve diseases and aortic stenosis is providing lucrative growth opportunities for the key operating companies. Companies involved in tricuspid valve repair devices are moving towards minimally invasive surgeries from invasive open heart surgeries. Minimally invasive surgeries reduces post-operative complications and minimize the associated risk.

Equipment developed by manufacturing companies such as transcatheter tricuspid valve repair system is yet to be approved by the regulatory bodies for patient use. However, these equipment are preferred in clinical trials according to key inputs provided by heart surgeons. 

For example, Abbott’s transcatheter tricuspid valve repair system (TTVR), TriClip has been clinically tested in patients suffering from severe tricuspid regurgitation. The system is found to be efficient for tricuspid valve repair in case of patients who are above 60 years of age, and cannot undergo open heart surgery for tricuspid valve repair.

Minimally invasive surgeries are likely to change the conventional way of treatment. The segment is likely to dominate in the global tricuspid repair market. 

Hospital is likely to capture 88% of the entire market share. The segment is anticipated to show positive growth rate in forthcoming years. However, the segment is likely to maintain its hegemony on back of growing minimally invasive surgery and prevalent open heart surgeries.

In forthcoming years, tricuspid valve repair market is estimated to witness significant growth rate. The growth rate is attributed to on-going research and development activities for innovation of the products aiming for the treatment of patients with tricuspid valve defects. Medical Device Companies and other stake holders operating in tricuspid valve repair market is investing extensively for invention of technically and scientifically advanced medical devices. For instance, Edwards Life Sciences Corporation is investing for development of structural heart therapies. This, in turn, has resulted in development of several breakthrough therapies. Some of these therapies are still being clinically evaluated.

Similarly, innovation aiming to develop annuloplasty ring is going on. The rings are manufactured using novel materials such as titanium alloy, polyesters, and other similar materials. Developments in the product aims to make the device flexible and durable. Further, innovation in design and share of the ring will help to avoid any kind of interference with heart conduction system. Source